The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Depends how much you need to raise and what the market cap is. GDR burns lots of cash although they have a product. On the other hand if Valirx can get a decent share price in the next few months then relative to the market it will be inconsequential.
WCB, Learn to read first as it is clear I was talking about Porky on this occasion.
I am glad you are still here. Clearly you see plenty of value here. You probably have nothing to do other than post on a stock you are not invested in during your retired days.
Enjoy your day and stop obsessing over me.
I have not bothered to read posts as it will just tempt me to respond to nonsense.
We have gone past the stage of deramping to get in cheaper because if the share price drops more they will only be able to raise a lower amount of money which then means you will be hit with another placing soon after. Ideally we want this to be at least 10p so if they did another placing next year it will be the last one given how many compounds we would have at a decent stage by then.
Knowing Porky he does not understand this concept.
I must also say it will make them all look very unprofessional if they were simply not trying. You cannot wipe out a bad reputation but at least if you left on a high you would have a selling point for future interviews and show how despite all the negative feelings you did your best and acted professionally which resulted in positive outcomes. That would really show a good character and would to some degree change feelings.
Is it in July we get the chance to vote on BOD members. It was projected that we have enough cash until the end of Q1 2025 so clearly no placing without news and at this time.
So the question is if by July no news is released then they would have conceded without trying as they get voted out with 0% support. But if they make a genuine effort including improving public communication which I suspect they will then they are needed and I am sure if Valirx goes back to at least 10p they will get support.
Therefore my conclusion is that we will see significant news shortly and I guess that is what they are waiting for. No de-listing unless it crashed from here because even if they raised 1 million is peanuts which they could last about 8 months with that after the next placing likely next year.
It really will not take much news to move this from the current market cap but the question is whether they want to move it or not.
OK thanks I noticed it a few days back. I don't see how it would be relevant to the merger as it would have to be announced
so it must still be going ahead.
Any takeover needs to be cash only no shares.
It would be good to know if TRX has the funding in place or not. Irrespective of whether the merger goes ahead it would go a long way if we could get a bit more information regarding the funding situation. I don't see why that has to be kept secret.
Get TRX to invest in Valirx as well and buy shares to help the recovery.
Surely with no lab contracts lots must be due with updates on either 301, CLX or new compounds due soon. They would have to do a really bad job if this was to go further down after the next update.
Not really interested in knowing about constant board changes. We need a real update regarding the work being done and intentions moving forwards.
TRX/EUDA can literally buy the lot for 10p and make a killing over at EUDA medium term. We will not go bust yet as our spend is relatively low and if it did drop more they can easily put an offer in as we got valuable compounds that are hard to find plus if they really want 201 it will save them money.
I just think it was stupid decision to put the person behind most of the action onto the BOD when he depends on the remaining members especially if they think they are next. Bit of a cat and mouse game but could have been dealt with much better.
Might as well look to sell the company to EUDA given where we are with all this.
That is the problem. He has no knowledge or understanding on a scientific level so he depends on the remaining BOD members to feed him. Not convinced he understands AIM that well either. They will make the calls and it is for that reason why asking Suzy to leave at this moment of time was wrong. You can remove the remaining guys now but again it achieves nothing.
I don't get the point of constantly moaning when changes have been made all at the wrong time.
We should get an update this week. I would imagine we get lots of news all due before any need for further cash.
If the merger completes then 201 should complete. The 201 deal is ongoing so still subject to the merger completing. If it was not they would have had to tell us. Entirely relevant and EUDA are currently worth $47 million based on not much so clearly they are expecting big things shortly which hopefully should reflect on our market cap when completed.
Also if a company is worth 50/60/70 million not only would they likely have cashed raised to complete the merger therefore the deals if they needed to raise an extra million or two to make sure Val was paid then this would be possible without hardly any dilution. I would expect that they have the cash for the trials from TRX for the merger to complete.
The chances still remain good but only time will tell.
For the legal team to accept this is significant and merger should therefore be completed.
Euda Health Adjusts Legal Fees, Issues Shares to CounselCompany Announcements
Euda Health Adjusts Legal Fees, Issues Shares to Counsel
TipRanks Newsdesk
TipRanks Newsdesk
Apr 30, 2024, 10:31 PM
Euda Health Holdings Limited (EUDA) has released an update.
You May Like
Explore attractive offers on the electric Volvo XC40
Volvo Cars
|
Sponsored
Uncovered: People Are Now Ditching Their Glasses for This in April
Lasik Eyes
|
Sponsored
How To Invest In Whisky. Own A Barrel Of Whisky
British Investing
|
Sponsored
Unsold 2024 Bargain Holiday Packages Are Now At Reduced Prices
Favorite Searches
|
Sponsored
Euda Health Holdings Limited has amended its agreement with Loeb & Loeb LLP, increasing the legal fee to $900,000 for services related to a business combination transaction. The fee adjustment includes issuing 60,000 restricted ordinary shares to Loeb and entering into a promissory note for $300,000. This comprehensive legal arrangement covers aspects from fee payment to share transfer regulations, ensuring compliance with U.S. securities laws.
Never a good idea if one is forcing board members to resign only to put himself on the board with no relevant experience. Not sure what everyone is expecting in this situation.
When Stella resigned one should have taken the position and then analysed what was going on. Based on that you would act.
Quick to assume failure. This is drug development not some supermarket where you pick things from the shelf. Trial and testing and timings are often over exaggerated.
Still very much open could go either way but at this market cap only one success is needed for a multi bagger.